CSL (OTCMKTS:CSLLY) Downgraded by Zacks Research to “Strong Sell”

Zacks Research cut shares of CSL (OTCMKTS:CSLLY) from a hold rating to a strong sell rating in a report issued on Monday,Zacks.com reports.

CSL Stock Performance

CSL stock opened at $67.04 on Monday. CSL has a 52 week low of $64.68 and a 52 week high of $101.44. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The stock has a 50-day simple moving average of $78.63 and a 200 day simple moving average of $78.67.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.